Kyle R. Crassini
Adelaide, SA, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.
Journal: Internal medicine journal
Published: January 06, 2026
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.
Journal: Internal medicine journal
Published: June 03, 2024
The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
Journal: Leukemia & lymphoma
Published: January 16, 2024
Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.
Journal: Internal medicine journal
Published: February 18, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Journal: Internal medicine journal
Published: November 30, 2022
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.
Journal: EJHaem
Published: July 14, 2020
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: December 04, 2019
Molecular pathogenesis of chronic lymphocytic leukaemia.
Journal: British journal of haematology
Published: August 01, 2019
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.
Journal: Leukemia & lymphoma
Published: January 17, 2019
Immune failure, infection and survival in chronic lymphocytic leukemia.
Journal: Haematologica
Published: July 05, 2018
Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
Journal: Leukemia & lymphoma
Published: June 19, 2018
Last Updated: 09/26/2026